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The age of addiction
It used to be considered daring for 
addiction researchers to bring illicit 
drugs and alcohol together—the 
banned substances talked of in the 
same breath as the one which many 
societies saw as acceptable. That 
hesitancy is long gone, undermined 
in part by David Courtwright’s 2001 
book Forces of Habit: Drugs and the 
Making of the Modern World, which 
covered the global histories of both 
sets of substances along with caffeine 
and a nod towards licit drugs. Out in 
the non-historical world, researchers 
and commentators began to question 
the nature of the boundaries between 
substances and how they had been 
constructed, with some licit, others 
prohibited. And in recent years, some 
of those boundaries have shifted 
again in some countries: coca and its 
acceptability in Bolivia, for example, or 
the legalisation of cannabis in various 
ways in certain US states, Canada, and 
some other countries.
Historians were also trying to 
understand how the separation of 
substances had come about. They 
started to look at a wider range 
of substances and activities that 
sought pleasure and the alteration 
of consciousness. A pioneer in the 
field was the American historian 
John Burnham with his book Bad 
Habits: Drinking, Smoking, Taking Drugs, 
Gambling, Sexual Misbehavior, and 
Swearing in American History, published 
in 1993. Burnham argued that vices 
which respectable people had once 
associated with the male underworld, 
and which Victorian and progressive 
reformers had marginalised, came 
back into the mainstream after the 
repeal of Prohibition in the USA. 
Burnham’s comparison was country 
specific. Now Courtwright has cast 
the net even wider. In his new book 
The Age of Addiction: How Bad Habits 
Became Big Business, he looks globally 
at how the quest for pleasure has 
brought an ever expanding range of 
activities into view. The book covers 
opioids, processed foods, social media 
pathways, gambling, other drugs, 
alcohol, smoking, and sex. The unifying 
ideas of the book are addiction, of 
course, and something Courtwright 
calls “limbic capitalism”. Addiction, a 
social as well as biological process, is an 
indispensable profit centre for a range 
of global businesses. More than that, 
Courtwright argues, global industries, 
working with amenable governments 
and criminal organisations, aim to 
encourage overconsumption and 
addiction. They do this with products 
that “target the limbic system, the 
part of the brain responsible for feeling 
and for quick reaction as distinct 
from dispassionate thinking”. Genetic 
variations, Courtwright argues, and 
life circumstances make some people 
more susceptible to addiction than 
others. This is a process of accelerating 
change over a long period of time. 
Civilisation incubated the technologies 
that quickened the global quest for 
pleasure, most recently through the 
explosion of digital communication.
What lies behind it all is that familiar 
public health bogeyman of industry. 
Whether it’s the two companies 
discussed in the book—Diageo pushing 
alcohol or the Sacklers’ firm Purdue 
Pharma fuelling the opioid crisis—the 
enemy is clear: it’s big business on a 
global scale reconfiguring our brains. 
Can we do anything about it? 
Courtwright thinks we can. In an 
interactive question and answer final 
section of the book called “Against 
Excess”, he sets out an agenda that 
could unite both right and left of the 
political spectrum. The agenda strikes 
a familiar note to this British public 
health historian. It’s the well known 
trio of advertising controls, higher 
taxes, and education. 
So the message of the book is 
clear and it is written with a wealth 
of different national examples in 
Courtwright’s trademark readable 
style. Yet I found that it raised 
some questions for me about the 
argument. The first question is about 
Courtwright’s unwavering faith in 
the neuroscience approach. The 
hero of recent history in this book is 
Nora Volkow, Director of the National 
Institute on Drug Abuse (NIDA) at the 
US National Institutes of Health and 
a leading addiction neuroscientist. 
Volkow, together with Alan Leshner, 
Director of NIDA from 1994 to 2001, 
both of whom are singled out in the 
book, issued a call to arms for the 
brain disease model of addiction. In 
the late 1990s came Leshner’s rallying 
call, “Addiction is a brain disease and it 
matters”. Neuroscience approaches are 
common in many countries, but the rise 
of that approach has been of particular 
importance in the USA. Importantly, it 
gave legitimacy to a disease model of 
addiction and it could be argued that 
addiction was treatable. In the UK, by 
contrast, HIV/AIDS had redefined drug 
use as a public health issue and there 
was a long history of disease views of 
addiction and an established treat-
ment system. Neuroscience didn’t have 
quite the same purchase as a facilitator 
of the argument for treatment. 
Historians have questioned the 
uncritical acceptance of the neuro-
science model both in general and 
specifically by Courtwright. The 
historian’s usual mindset is to ask 
why particular ideas achieve salience 
at particular points in time and in 
specific contexts, and not just to 
accept them wholesale. Historian 
Jim Mills, for example, wrote of an 
earlier articulation by Courtwright of 
“Addiction, a social as well as 
biological process, is an 
indispensable profit centre for 
a range of global businesses.”
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the ideas in this book “the tone of the 
argument seems to implicitly accept 
that this knowledge is ‘true’ and it 
fails to explore the forces which have…
driven science in this direction. Many 
factors suggest themselves, amongst 
which are the financial commitment to 
the ‘ war on drugs’ of the United States, 
the consolidation and expansion of 
pharmaceutical corporations eager to 
open new markets in ‘limbic capitalism’ 
or the morality of the post-AIDS 
generation of the 1980s which was 
forced to reassess its pleasures within 
the calculus of cost to health.” Historian 
Tim Hickman has likewise been critical 
of the dominance of brain science as 
a form of explanation for addiction, 
drawing parallels between current 
neuroscience and the brain theories 
that animated the patent medicine 
salesman Leslie Keeley with his “Keeley 
cure” in the 1890s. Moving beyond the 
historical critique, Courtwright to some 
extent seems to advance ideas that 
have some parallels with the concept 
of the “configured user”—the notion 
of the way in which the brain adapted 
to new technologies, configured itself 
differently in response to them, which 
was common in science and technology 
studies to explain their appeal. 
The second question relates to 
structures and cross-national dif-
ferences. The Age of Addiction is to 
some extent unappreciative of the 
differences in national institutions 
and in regulations that drive divergent 
policy responses. Diageo, mentioned 
in the book, is a global alcohol brand, 
but it has to operate in different 
regulatory environments—for example, 
it would comply with minimum unit 
pricing in Scotland. The Sacklers and 
their company, also discussed in the 
book, are blamed for initiating the 
opioid crisis in the USA, charitable 
opportunities are withdrawn, and 
law suits launched. But there is less 
discussion in the book of the US health-
care system. Insurance companies 
trying to limit costs had promoted pain 
medication over physical therapy and 
the absence of addiction treatment 
services facilitated a transition to heroin 
once pain medication was withdrawn. 
Direct-to-consumer advertising is less 
stringently regulated in the USA than 
in the UK, where it cannot happen, 
although online sales are increasing. 
The industry does not operate in 
isolation and different national 
histories of regulation and of public 
health mean a lot—as the contrast 
between the USA and the UK indicates. 
The role of government in regulation 
and public health in evidence-based 
treatment, prevention, and harm 
reduction and the history of how those 
responses have evolved and how they 
differ are important. This context, I 
would argue, could have been given 
more weight in the analysis in this 
book, which tends to be US centric in 
its perspective despite the wealth of 
cross-national examples.
And, finally, the third question. 
How new is the public health part of 
this agenda outside the USA? And 
what do we mean by public health? 
Courtwright’s solution is a traditional 
public health one of advertising 
controls, taxation, and education—
with prohibition, he argues, as the 
ideal but probably unachievable 
backstop. This agenda has largely been 
the model for public health in the UK 
and at the international level—for 
example, through WHO declarations 
on smoking and alcohol since the 
1970s. It has operated with some 
success for tobacco control with a 
substantial decline in smoking over 
time, and it is beginning to impact on 
alcohol and on sugar. This approach 
has not been the case in the USA, 
which has relied on controls through 
the law courts with weaker federal 
structures. Regulation of advertising 
falls foul of US commitment to 
freedom of speech. Courtwright’s 
agenda may be radical for the USA, 
but it has been mainstream in 
public health in the UK and at the 
international level.
And maybe times are changing. 
There is curiously little in the book 
about the legalisation of cannabis 
in which some US states have been 
pioneers, and where further industrial 
interests are now emergent. The 
current debate in these contexts is 
about how commercial companies are 
to be regulated and how cannabis is 
to be marketed. Legalising cannabis in 
the USA has created an industry with 
a direct interest in promoting regular 
cannabis use. Cannabis potency is 
largely unregulated and prices have 
fallen steeply. Here is an example of 
the rise and fall of addictions and 
industries as cannabis, vaping, and the 
Shisha pipe to some extent supplant 
tobacco smoking. Nor is there much 
about harm reduction in the book, 
which failed to develop as a national 
policy in the USA for drugs and HIV 
in the 1980s. One battleground now 
is over nicotine, where Courtwright 
cites national bans on e-cigarettes and 
vaping in 30 different countries with 
approval. Here, the British response 
of harm reduction through the use 
of nicotine is in stark contrast to the 
current US reaction to the vaping 
epidemic. US vaping problems and 
current concerns about lung injuries 
and the spread of vaping among young 
people again stem partly from less 
regulation by comparison with the UK, 
with tetrahydrocannabinol and vitamin 
E contaminating the substances vaped. 
Britain—subject to both EU and national 
regulations with a lower allowable 
nicotine level in consumer products 
and restrictions on advertising—differs 
from the US situation.
The Age of Addiction is an engagingly 
written book with a clear message. 
In essence, Courtwright calls for a 
return to the anti-vice activism that 
operated more than a century ago, the 
history of which the book covers. Only 
this time it is public health, rooted in 
neuroscience, that Courtwright sees 
as taking on the battle. This is a call 
with its main resonance in the USA. 
Whether it becomes a universal public 
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